| Michele Howland Jones, OTR | |
|
318 E Basin Rd, New Castle, DE 19720-4214 | |
| (302) 323-2700 | |
| Not Available |
| Full Name | Michele Howland Jones |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 318 E Basin Rd, New Castle, Delaware |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255729240 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | U1-0000628 (Delaware) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Michele Howland Jones, OTR 318 E Basin Rd, New Castle, DE 19720-4214 Ph: () - | Michele Howland Jones, OTR 318 E Basin Rd, New Castle, DE 19720-4214 Ph: (302) 323-2700 |
News Archive
Blood clots continue to wreak havoc for patients with severe COVID-19 infection, and a new study explains what may spark them in up to half of patients.
Researchers at UT Southwestern Medical Center have found an enzyme vital for controlling the early stages of cell death - a beneficial and normal process when it works right, but malignant in a variety of cancers when it malfunctions.
A new genome-wide association study of more than 6,000 people has identified seven new genetic regions associated with pulmonary fibrosis. In findings published online in Nature Genetics on April 14, 2013, researchers at National Jewish Health, the University of Colorado and several other institutions found a number of genes associated with host defense, cell-cell adhesion and DNA repair, which provide clues to possible mechanisms underlying this currently untreatable disease.
Scientists at The University of Texas M. D. Anderson Cancer Center have identified a protein that serves as a master regulator of skin cancer - a finding that could lead to new ways to prevent skin cancer before it starts.
Pfizer Inc. announced today the publication of data showing that 57 percent of ALK-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib (PF-02341066), an investigational oral anaplastic lymphoma kinase (ALK) inhibitor, had either a complete (one patient) or partial (46 patients) response to treatment. Data from 82 patients in this Part 2 expansion cohort of the Phase 1 study were published in the October 28 issue of the New England Journal of Medicine.
› Verified 1 days ago
Heidi Baist, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 318 E Basin Rd, New Castle, DE 19720 Phone: 302-323-2793 | |
Mr. Steven Gockman, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 318 E Basin Rd, New Castle, DE 19720 Phone: 302-323-2700 | |
Jac Lyn Garyantes, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 318 E Basin Rd, New Castle, DE 19720 Phone: 302-323-2700 | |
Dr. Haley Mcgrath, OTD, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 200 E Roosevelt Ave, New Castle, DE 19720 Phone: 302-323-2901 | |
Jenna Talley, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 15 Reads Way, New Castle, DE 19720 Phone: 302-322-2300 | |
Jessica Ann Scarmozzi, MS, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 904 Churchmans Road Ext, New Castle, DE 19720 Phone: 302-323-1118 Fax: 302-323-1173 | |
Kristen May Maltman, M.S. OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 318 E Basin Rd, New Castle, DE 19720 Phone: 302-323-2700 |